TY - JOUR
T1 - Comparison of the effects of omeprazole and famotidine in treatment of upper abdominal symptoms in patients with reflux esophagitis
AU - Kusunoki, Hiroaki
AU - Kusaka, Masayasu
AU - Kido, Soichiro
AU - Yamauchi, Ryo
AU - Fujimura, Yoshinori
AU - Watanabe, Yasuyuki
AU - Kobori, Michio
AU - Miwa, Hiroto
AU - Tomita, Toshihiko
AU - Kin, Yongmin
AU - Hori, Kazutoshi
AU - Tano, Nobuo
AU - Sugimoto, Kenji
AU - Nakamura, Yoshihiro
AU - Fujimoto, Kazuma
AU - Oza, Noriko
AU - Matsunobu, Aki
AU - Ono, Naofumi
AU - Fuyuno, Seisuke
AU - Kinoshita, Yoshikazu
AU - Adachi, Kyoichi
AU - Yuki, Mika
AU - Fujisawa, Tomoo
AU - Haruma, Ken
PY - 2009
Y1 - 2009
N2 - Purpose: The purpose of this study was to compare the efficacy of proton pump inhibitor (PPI) with H2 receptor antagonist (H2RA) in treatment of upper abdominal symptoms. Methods: This was a multi-center, open study conducted at 102 hospitals in Japan. Patients with reflux esophagitis received famotidine 10 mg twice daily for 2 weeks, then omeprazole 10 mg once daily for 2 weeks. Thereafter, patients were switched to famotidine 10 mg twice daily for a third 2-weekperiod, provided those with a medical condition agreed to continue the study. Patients evaluated the treatment response to each gastrointestinal symptom using a predefined patient questionnaire and gastrointestinal symptom rating scale (GSRS). Results: 161 patients entered the study, of whom 8 were excluded from all analyses due to lack of participation following entry. Overall symptom improvement rate (n = 130) at week 4, after the 2-week omeprazole treatment, was 75.4% and this was significantly higher than that after the first 2-week famotidine treatment (41.5%) at week 2. In patients (n = 36) who completed 6 weeks of treatment, 2-week omeprazole treatment at week 4 showed a significantly higher overall symptom improvement rate compared with both the first 2-week and third 2-week famotidine treatments. Conclusions: Omeprazole was superior to famotidine for treatment of upper abdominal symptoms in patients with reflux esophagitis, which suggested that gastric acid might be a cause not only of reflux symptoms, but also of ulcer symptoms and dysmotility symptoms such as epigastric pain and feeling of fullness in reflux esophagitis.
AB - Purpose: The purpose of this study was to compare the efficacy of proton pump inhibitor (PPI) with H2 receptor antagonist (H2RA) in treatment of upper abdominal symptoms. Methods: This was a multi-center, open study conducted at 102 hospitals in Japan. Patients with reflux esophagitis received famotidine 10 mg twice daily for 2 weeks, then omeprazole 10 mg once daily for 2 weeks. Thereafter, patients were switched to famotidine 10 mg twice daily for a third 2-weekperiod, provided those with a medical condition agreed to continue the study. Patients evaluated the treatment response to each gastrointestinal symptom using a predefined patient questionnaire and gastrointestinal symptom rating scale (GSRS). Results: 161 patients entered the study, of whom 8 were excluded from all analyses due to lack of participation following entry. Overall symptom improvement rate (n = 130) at week 4, after the 2-week omeprazole treatment, was 75.4% and this was significantly higher than that after the first 2-week famotidine treatment (41.5%) at week 2. In patients (n = 36) who completed 6 weeks of treatment, 2-week omeprazole treatment at week 4 showed a significantly higher overall symptom improvement rate compared with both the first 2-week and third 2-week famotidine treatments. Conclusions: Omeprazole was superior to famotidine for treatment of upper abdominal symptoms in patients with reflux esophagitis, which suggested that gastric acid might be a cause not only of reflux symptoms, but also of ulcer symptoms and dysmotility symptoms such as epigastric pain and feeling of fullness in reflux esophagitis.
UR - http://www.scopus.com/inward/record.url?scp=65049089659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65049089659&partnerID=8YFLogxK
U2 - 10.1007/s00535-009-0003-4
DO - 10.1007/s00535-009-0003-4
M3 - Article
C2 - 19280112
AN - SCOPUS:65049089659
SN - 0944-1174
VL - 44
SP - 261
EP - 270
JO - Journal of Gastroenterology
JF - Journal of Gastroenterology
IS - 4
ER -